Abbott Laboratories Stock Fair Value – Abbott Laboratories to Lead Next Generation Implants Market by 2023
June 30, 2023
🌥️Trending News
Abbott Laboratories ($NYSE:ABT) is poised to be a leader in the next-generation implants market by 2023. Analysis of key players in the market reveals that Abbott Laboratories is expected to make significant strides within the next four years. The company has seen steady growth in this field, due to their continued investment in innovative medical advancements. Abbott Laboratories is an American healthcare company that specializes in the diagnostics, medical devices, and nutrition sectors. They offer a wide range of products including diagnostic tests, point-of-care (POC) testing, and nutrition products. They have also developed a number of surgical implants and medical devices which are used to improve patient care. The next-generation implants market is expected to grow significantly over the next few years, and Abbott Laboratories is well-positioned to take advantage of this growth. The company is already a leader in the industry with a wide range of products and services that will help healthcare providers provide better care for their patients.
In addition, they have an impressive network of partnerships, which will allow them to remain competitive in the face of increasing competition from other key players such as Arthrex and Medtronic. With their commitment to innovation and quality, Abbott Laboratories is sure to take a leading role in the next-generation implants market by 2023.
Share Price
On Thursday, Abbott Laboratories made a breakthrough in the medical industry as its stock opened at $107.0 and closed at $107.7. This marks the beginning of a new era of medical technology for the company, as it is expected to lead the next generation implants market by 2023. Abbott Laboratories is renowned for its innovative products and the latest advancement is set to further strengthen its presence in the healthcare industry. The new implants will be designed to improve patient safety, accuracy, and efficiency during medical procedures.
The company has invested heavily in research and development to ensure the highest quality standards for its products. Furthermore, Abbott Laboratories has already established a strong network of partners and distributors to support its expanding customer base. With these measures in place, Abbott Laboratories is poised to revolutionize the implants market and become a leader by 2023. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbott Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 41.51k | 5.8k | 14.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbott Laboratories. More…
| Operations | Investing | Financing |
| 9.58k | -1.74k | -7.64k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 74.44k | 37.53k | 21.11 |
Key Ratios Snapshot
Some of the financial key ratios for Abbott Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.9% | 15.2% | 18.0% |
| FCF Margin | ROE | ROA |
| 18.8% | 12.7% | 6.3% |
Analysis – Abbott Laboratories Stock Fair Value
GoodWhale has conducted an in-depth analysis of ABBOTT LABORATORIES‘s wellbeing, taking into account its financials, its operations and its expected growth. We believe that the intrinsic value of ABBOTT LABORATORIES share is around $116.8. This is calculated using GoodWhale’s proprietary Valuation Line, which assesses the company’s underlying business fundamentals. Currently, ABBOTT LABORATORIES is trading at a fair price of $107.7, which is slightly below its intrinsic value by 7.8%. More…
Peers
Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.
– OraSure Technologies Inc ($NASDAQ:OSUR)
OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.
OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.
– Quidel Corp ($NASDAQ:QDEL)
Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.
– Lucira Health Inc ($NASDAQ:LHDX)
Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.
Summary
ABBOTT Laboratories is an American healthcare company that specializes in medical devices, diagnostic equipment, and nutrition products. The company is well-positioned to benefit from the growing demand for next-generation medical implants, as well as from advances in medical technology. ABBOTT has a strong portfolio of innovative products and services that are expected to drive long-term growth and profits. The company is investing heavily in research and development, and in customer service, to ensure its products remain attractive to customers.
ABBOTT’s financial performance is also positive, with strong top-line growth and healthy earnings. The company is well-positioned to benefit from the strong market demand for medical implants and other innovative products and services, making it an attractive investment.
